Oventus Medical Limited (ASX:OVN) founder, Managing Director and CEO, Dr Chris Hart discusses the company's sales push into the US, new product development and changes in the treatment of sleep apnoea at FNN's Investor Event.
Key points:- Oventus is commercialising its O2Vent™ to treat Obstructive Sleep Apnoea
- Breathing is briefly interrupted or becomes very shallow during sleep
- 80 per cent of sleep apnoea sufferers are currently out of care
- Conventional treatment can be intolerable
- 100 per cent patients treated without using a full face mask
- Distribution agreement with Modern Dental Group
For more, watch founder, Managing Director and CEO, Dr Chris Hart present.
